Denis Chem Lab Ltd
Incorporated in 1982, Denis Chem Lab Ltd does manufacturing of Pharmaceuticals Transfusion Solution in Bottles[1]
- Market Cap ₹ 126 Cr.
- Current Price ₹ 90.5
- High / Low ₹ 193 / 88.0
- Stock P/E 15.5
- Book Value ₹ 61.3
- Dividend Yield 1.66 %
- ROCE 20.1 %
- ROE 14.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 33.2%
Cons
- Promoter holding is low: 39.0%
- Company has a low return on equity of 12.0% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
55 | 67 | 75 | 98 | 112 | 107 | 123 | 135 | 109 | 136 | 161 | 167 | 173 | |
49 | 60 | 66 | 89 | 98 | 95 | 110 | 120 | 99 | 122 | 142 | 146 | 157 | |
Operating Profit | 6 | 6 | 9 | 8 | 14 | 12 | 14 | 15 | 10 | 14 | 19 | 21 | 16 |
OPM % | 11% | 9% | 12% | 9% | 12% | 11% | 11% | 11% | 9% | 11% | 12% | 13% | 9% |
0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 2 | |
Interest | 2 | 3 | 5 | 7 | 6 | 5 | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
Depreciation | 1 | 1 | 4 | 6 | 7 | 6 | 6 | 7 | 6 | 6 | 8 | 7 | 7 |
Profit before tax | 3 | 2 | 0 | -3 | 2 | 2 | 6 | 6 | 3 | 9 | 11 | 15 | 11 |
Tax % | 34% | 41% | 78% | 30% | 37% | -5% | -7% | 26% | 27% | 30% | 28% | 26% | |
2 | 1 | 0 | -4 | 1 | 2 | 6 | 4 | 2 | 6 | 8 | 11 | 8 | |
EPS in Rs | 3.11 | 1.17 | 0.07 | -4.16 | 0.89 | 1.54 | 4.58 | 3.03 | 1.63 | 4.51 | 5.66 | 8.04 | 5.82 |
Dividend Payout % | 18% | 0% | 0% | 0% | 0% | 0% | 22% | 0% | 46% | 33% | 35% | 31% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 6% |
3 Years: | 15% |
TTM: | 3% |
Compounded Profit Growth | |
---|---|
10 Years: | 24% |
5 Years: | 15% |
3 Years: | 70% |
TTM: | -28% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 14% |
3 Years: | 11% |
1 Year: | -50% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 10% |
3 Years: | 12% |
Last Year: | 15% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 3 | 9 | 9 | 12 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Reserves | 7 | 6 | 8 | 7 | 18 | 36 | 43 | 45 | 48 | 53 | 58 | 66 | 69 |
17 | 31 | 48 | 44 | 37 | 25 | 23 | 14 | 9 | 3 | 2 | 1 | 4 | |
10 | 12 | 17 | 24 | 27 | 26 | 26 | 25 | 22 | 27 | 25 | 28 | 31 | |
Total Liabilities | 35 | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 109 | 118 |
10 | 9 | 42 | 40 | 44 | 40 | 50 | 46 | 41 | 42 | 35 | 38 | 36 | |
CWIP | 0 | 9 | 0 | 10 | 1 | 5 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
25 | 34 | 39 | 35 | 49 | 56 | 55 | 52 | 51 | 55 | 62 | 72 | 81 | |
Total Assets | 35 | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 109 | 118 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1 | -2 | 14 | 21 | 7 | 11 | 8 | 13 | 8 | 17 | 16 | 18 | |
-1 | -9 | -28 | -13 | -1 | -16 | -2 | -2 | -1 | -10 | -11 | -15 | |
4 | 12 | 13 | -7 | -0 | 1 | -5 | -14 | -6 | -7 | -4 | -4 | |
Net Cash Flow | 1 | 0 | -1 | 1 | 5 | -4 | 1 | -3 | 1 | -0 | 1 | -1 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 111 | 91 | 123 | 85 | 104 | 105 | 106 | 94 | 110 | 85 | 71 | 69 |
Inventory Days | 40 | 37 | 40 | 39 | 35 | 52 | 50 | 51 | 60 | 50 | 39 | 43 |
Days Payable | 60 | 53 | 81 | 119 | 136 | 150 | 102 | 108 | 103 | 99 | 79 | 90 |
Cash Conversion Cycle | 90 | 75 | 81 | 4 | 3 | 8 | 55 | 37 | 67 | 36 | 31 | 22 |
Working Capital Days | 2 | 32 | -19 | -57 | -13 | 4 | 17 | 32 | 63 | 51 | 41 | 38 |
ROCE % | 22% | 16% | 11% | 5% | 12% | 9% | 11% | 11% | 6% | 14% | 16% | 20% |
Documents
Announcements
-
Board Meeting Intimation for Taking On Record Unaudited Financial Results For The Quarter Ended On 30Th June, 2025.
5 Aug - Board meeting on 13 Aug 2025 to approve Q1 unaudited financial results; trading window remains closed.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 Jul - Clipping of Newspaper advertisement published on 29th July, 2025 for your information and records.
-
Shareholder Meeting - 44Th Annual General Meeting On 26Th September, 2025
26 Jul - 44th AGM on 26 Sept 2025; record date 19 Sept; new secretarial and cost auditors appointed.
-
Corporate Action- Fixes Record Date For Final Dividend.
26 Jul - 44th AGM on 26 Sept 2025; record date 19 Sept for dividend; new secretarial and cost auditors appointed.
-
Announcement Under Regulation 30 (LODR) - Outcome Of Board Meeting
26 Jul - AGM on 26 Sep 2025, record date 19 Sep, dividend & auditor appointments announced.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
DCLL manufactures and markets sterile Intravenous injectibles in Glass and Plastic Bottles for human and veterinary consumption. It also manufactures products on contract basis for multinational pharmaceutical companies who market them under their own brands. Company has a fully equipped in-house Quality Control Laboratory having different interdepartments for Chemical Testing, Physico-Chemical Testing, Microbiological Testing, Pyrogens Testing, Sterility Testing and Toxicity Testing. All raw materials, packaging materials, in process testing and finished stocks are tested in-house.